Sharekhan's research report on Insecticides (India) Ltd
Q4FY23 results were weak as a net loss of Rs. 29 crore was significantly higher than our estimate of net loss of Rs. 4 crore due to negative OPM of 9.4% given the hit from provisions on liquidation of high-cost inventory and a mark-to-market (MTM) loss of Rs. 15-20 crore. Management guided revenue growth of 10-12% and subdued EBITDA margin of 9-10% (lower than 11-12% historically) for FY24 as liquidation of high-cost inventory would continue in Q1FY24. Ramp-up of recently commissioned capacity expansion at Chopanki & new products along with recovery in export revenues could drive earnings recovery over Q2FY24-FY25. We cut our FY24/FY25 earnings estimate sharply by 28%/22% to factor lower revenue/margin guidance which reflects near-term concerns amid high channel inventory and product prices pressure given excess supply from China.
Outlook
The steep 40% fall in stock price in CY23YTD largely factors in margin concerns. Ramp-up of new capacity and recovery in export revenue could drive earnings recovery from Q2FY24. Hence, we maintain a Buy on Insecticides (India) but with a lower PT of Rs. 540. Valuation of 13x/9x its FY2024E/FY2025E EPS is attractive.
For all recommendations report, click here
Disclaimer: The views and investment tips expressed by investment experts/broking houses/rating agencies on moneycontrol.com are their own, and not that of the website or its management. Moneycontrol.com advises users to check with certified experts before taking any investment decisions.
Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
Find the best of Al News in one place, specially curated for you every weekend.
Stay on top of the latest tech trends and biggest startup news.